David Ziegler

Professor

University of New South Wales
Country flagAustralia
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (28)

Paediatric central nervous system (CNS) tumours are the leading cause of cancer-related death in children, yet disease monitoring remains challenging. Conventional approaches, including imaging and cytology, lack sensitivity, delaying intervention. Liquid biopsy offers a minimally invasive alternative, but the utility of circulating tumour cells (CTCs) in paediatric CNS tumours as biomarkers is poorly defined. We developed a CTC detection and characterisation workflow from cerebrospinal fluid (CSF) utilising single-cell RNA-sequencing (scRNA-seq) and applied this to ten CNS tumour subtypes in 16 patients. CTCs were identified in all cases, with higher burdens in pineoblastoma, medulloblastoma and atypical teratoid rhabdoid tumours. Longitudinal profiling revealed CTC dynamics correlated with clinical disease course and anticipated relapse. Critically, scRNA-seq uncovered a sub-clonal canonical driver alteration at diagnosis that only became detectable by bulk RNA-seq at progression, underscoring its potential to resolve clonal dynamics. This workflow enables real-time molecular profiling, offering a transformative strategy for disease monitoring and personalised therapy in paediatric brain tumours.

Year:

2025

METRO results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 250kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)

Year:

2025

Purpose: High-grade gliomas (HGG) occur in any central nervous system location and at any age. HGGs in teenagers/young adults (TYA) are understudied. This project aimed to characterize these tumors to support accurate stratification of patients. Experimental Design: 207 histone/IDH wild-type tumors from patients aged 13 to 30 years were collected. DNA methylation profiling [Illumina EPIC BeadArrays, brain tumor classifier (MNPv12.8 R package)] classified cases against reference cohorts of HGG. Calibrated scores guided characterization workflows [RNA-based ArcherDx fusion panel ( n = 92), whole-exome sequencing ( n = 107), and histology review). Results: 53.4% ( n = 86) matched as pediatric-type subgroups [pedHGG_RTK1A/B/C (31.7%, n = 51, PDGFRA , CDKN2A/B , SETD2 , and NF1 alterations), pedHGG_ MYCN (8.1%, n = 13, MYCN/ID2 amplifications), and pedHGG_RTK2A/B (7.5%, n = 12, TP53 , BCOR , ATRX , and EGFR alterations)]. Eighteen percent ( n = 29) classified as adult-type subgroups [GBM_MES (15.5%, n = 25, enriched for RB1 , PTEN , and NF1 alterations) and GBM_RTK1/2 (2.5%, n = 4, CDK4 amplifications)]. Twenty-three cases (14.7%) classified as novel, poorly characterized subgroups with distinct methylation profiles and molecular features [pedHGG_A/B ( n = 10 6.2%), HGG_E ( n = 6 3.7%), HGG_B ( n = 2 1.0%), and GBM_CBM ( n = 5 3.1%)] with variable histologic morphology. Eight cases (5.1%) showed hypermutator phenotypes, enriched in HGG_E, one of which was associated with constitutional mismatch repair deficiency, and their sibling, who was diagnosed with the same syndrome, was diagnosed with a tumor that classified as a pedHGG_RTK1B. HGGs that have developed on a background of previous treatment for a childhood cancer are detected in the TYA population, classifying most frequently as pedHGG_RTK1 and contributing to the poor prognosis of this subgroup. Age distribution/molecular profile comparisons using publicly available methylation/sequencing data (and from local diagnostic cohorts) for HGG_B ( n = 19), GBM_CBM ( n = 35), and GBM_MES_ATYP ( n = 102), irrespective of age, show that HGG_B is a TYA-specific subgroup (median age 29 years) and that GBM_CBM and GBM_MES_ATYP show a peak of distribution in the TYA population but also have a wider age distribution (median age 35.7 and 50.5 years, respectively), with the latter showing distinct differences in copy-number profiles compared with older adults in the same subgroup and containing fewer chr7 gains, chr10 losses, more CDKN2A/B deletions and MET amplifications, and a worse survival compared with adult-specific GBM_MES_TYP. Conclusions: TYA HGGs comprise novel methylation subgroups with distinct methylation and molecular profiles. Accurate stratification of these patients will open opportunities to more effective treatments, including immune checkpoint, MAPK pathway, and PDGFRA inhibitors. See related commentary by Ritzmann et al., p. 3110

Year:

2025

METRO-Egger results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 500kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)

Year:

2025

METRO results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 500kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)

Year:

2025

METRO-Egger results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 250kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)

Year:

2025

Background: Hepatoblastoma (HB) is a rare embryonal liver tumor, with an increasing global incidence that underscores the need to understand its genetic etiology. Methods: Utilizing the ancestry-matched expression quantitative loci data, we performed a HB transcriptome-wide association study (TWAS) on 4,539 Europeans, 1,047 Latinos, and 378 African Americans (∼1:10 case–control ratio). We conducted a meta-analysis of multiancestry transcriptome-wide analysis (METRO), followed by METRO-Egger sensitivity analysis and ancestry-specific gene set enrichment analyses. We further explored genes with additional evidence gathered from independent cohorts and databases. Results: Across the three ancestries, the discovered genes shared the same effect direction across ancestries. A meta-analysis of the three ancestries identified 28 genes significantly associated with HB risk, and 15 were nominally significant for at least two ancestries. Our post-TWAS analyses highlighted 8 genes among these 28, including OXER1 (meta-analysis P value = 7.34 × 10 −6 ), FADS1 ( P value = 4.01 × 10 −6 ), and UGDH ( P value = 5.29 × 10 −8 ), which were expressed in fetal liver hepatoblast cells and were differentially expressed in tumor and normal tissues in an independent Japanese HB study (P values = 2.61 × 10 −13 , 3.62 × 10 −3 , and 1.95 × 10 −9 , respectively). Conclusions: We pinpointed eight potential genes associated with HB using data from an ongoing multiancestry genome-wide association study. Impact: We conducted the largest HB TWAS to date, prompting further exploration of genes.

Year:

2025

Supplementary figure 1 A, Bar plot showing the frequency of age distribution across the TYA cohort, and the gender proportions. Blue representing male, pink representing female. B, Pie chart representing the original diagnoses of the TYA cohort, coloured according to the labels provided.

Year:

2025

Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults ( P P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

Year:

2025

Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (84)

Daniel A. Morgenstern

Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Marcel Dinger

Dean

University of Sydney

AUSTRALIA
View details

CAROLINA ARMENGOL

Principal Investigator- Childhood Liver Oncology group

-

SPAIN
View details

Fatima Valdes-Mora

Team Leader

Children's Cancer Institute Australia

AUSTRALIA
View details

Jenny Poynter

Professor

University of Minnesota

UNITED STATES
View details

Roland Kappler

LMU University Hospital

GERMANY
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Ryuma Tanaka

Assistant Professor

Nationwide Children's Hospital

UNITED STATES
View details

Mariella Spalato Ceruso

Institut Bergonié

FRANCE
View details

David Malkin

University of Toronto

CANADA
View details

Jordan R Hansford

Oncologist

University of Melbourne

AUSTRALIA
View details

Tianzhong Yang

University of Minnesota

UNITED STATES
View details

Derek S. Tsang

Staff Radiation Oncologist

-

CANADA
View details

Uri Tabori

Section Head of Neuro-Oncology

Hospital for Sick Children

CANADA
View details

Frank Lin

Baylor College of Medicine Department of Pediatrics

UNITED STATES
View details

Holly Lindsay

Associate Professor

University of Colorado Health

UNITED STATES
View details

Ingrid Øra

MD, PhD, Assoc Prof

Lund University

SWEDEN
View details

Birgit Geoerger

Université Paris-Saclay

FRANCE
View details

Benjamin Rayner

Senior Scientist

Children's Cancer Institute Australia

AUSTRALIA
View details

David Lewis Lawrence

Conjoint Lecturer

UNSW Sydney

AUSTRALIA
View details

Maria Vinci

Principal Investigator

Ospedale Pediatrico Bambino Gesù

ITALY
View details

Eugene Hwang

Chief

Children's National Medical Center

UNITED STATES
View details

Alexander Drilon

Thomas Jefferson University Hospital

UNITED STATES
View details

Chantel Cacciotti

Western University

CANADA
View details

Chris Jones

Professor of Childhood Brain Tumour Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Maura Massimino

Direttore S.C

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Kathryn McFadden

Associate Clinical Professor

Izaak Walton Killam Health Centre

CANADA
View details

elisabetta schiavello

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Adam Shlien

Wellcome Sanger Institute

UNITED KINGDOM
View details

Daniel Orbach

-

FRANCE
View details

Paul Ekert

Group Leader, Translational Tumour Biology

Children's Cancer Institute Australia

AUSTRALIA
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Anita Villani

Hospital for Sick Children

CANADA
View details

Christopher L Moertel

University of Minnesota

UNITED STATES
View details

Nathan Robison

Assistant Professor of Clinical Pediatrics

University of Southern California Keck School of Medicine

UNITED STATES
View details

Maria Tsoli

Senior Scientist

Children's Cancer Institute Australia

AUSTRALIA
View details

Sebastian Brandner

University College London

UNITED KINGDOM
View details

Timothy N. Phoenix

Assistant Professor

University of Cincinnati

UNITED STATES
View details

Ute Bartels

University of Toronto

CANADA
View details

Eiso Hiyama

Professor

Hiroshima University

JAPAN
View details

Kim Erika Nichols

Full Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Nicholas Gottardo

University of Western Australia

AUSTRALIA
View details

Rawan Hammad

Assistant professor

king abdulaziz university

SAUDI ARABIA
View details

Gail Tomlinson

Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Nada Jabado

Professor

McGill University

CANADA
View details

Evelina Miele

Associate Medical Director

Ospedale Pediatrico Bambino Gesù

ITALY
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Mark Cowley

Conjoint Professor

University of New South Wales

AUSTRALIA
View details

Kathreena M Kurian

University of Bristol

UNITED KINGDOM
View details

Delphine Boche

Professor of Neuroimmunopathology

University of Southampton

UNITED KINGDOM
View details

Andrea T. Franson

-

UNITED STATES
View details

Saonli Basu

Professor

University of Minnesota

UNITED STATES
View details

Lenka Krsková

First Faculty of Medicine Charles University and University Hospital Motol

CZECH REPUBLIC
View details

Theodore Laetsch

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Michal Zapotocky

University Hospital in Motol

CZECH REPUBLIC
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Federico Roncaroli

The University of Manchester

UNITED KINGDOM
View details

Vanessa Tyrrell

Co-Head of Division - Peronalised Medicine

Children's Cancer Institute Australia

AUSTRALIA
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Erin L Marcotte

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Michael Scheurer

Professor

Baylor College of Medicine

UNITED STATES
View details

Audrey-Anne Lamoureux

Université de Montréal

CANADA
View details

Eric Bouffet

Neuro-Oncologist

Hospital for Sick Children

CANADA
View details

Donald Parsons

Professor

Baylor College of Medicine

UNITED STATES
View details

Birgit Ertl-Wagner

Radiologist-in-Chief

Hospital for Sick Children

CANADA
View details

Eve Roman

University of York

UNITED KINGDOM
View details

Alexander G. Weil

-

CANADA
View details

Holly Holliday

Children's Cancer Institute Australia

AUSTRALIA
View details

Wayne Nicholls

Clinical Director and Associate Professor

University of Queensland

AUSTRALIA
View details

Peter Downie

Head of Unit

Monash Health

AUSTRALIA
View details

Robert Weatheritt

Associate Professor

UNSW Sydney

AUSTRALIA
View details

Chelsea Mayoh

Children's Cancer Institute Australia

AUSTRALIA
View details

Vijay Ramaswamy

Associate Professor

University of Toronto

CANADA
View details

Trevor J. Pugh

Professor

University Health Network

CANADA
View details

CHI KIN IP

Children's Cancer Institute Australia

AUSTRALIA
View details

Anirban Das

Hospital for Sick Children

CANADA
View details

Logan Spector

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Marion Mateos

University of New South Wales

AUSTRALIA
View details

Peter B. Dirks

-

CANADA
View details

Darren Hargrave

University College London

UNITED KINGDOM
View details

Angela Mastronuzzi

Associate Professor

Università Cattolica del Sacro Cuore

ITALY
View details

Yosef Maruvka

Assistant professor

Technion - Israel Institute of Technology

ISRAEL
View details

R. Stephanie Huang

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Nicolas U. Gerber

University Children's Hospital Zurich

SWITZERLAND
View details